Search SABS
SAB Biotherapeutics, Inc.
Nasdaq, Nasdaq · CIK 1833214
Last close2.98
Daily change-0.08 (-2.61%)
10 Years gain-97.06%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SABS · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
26.5Momentum
0.0Acceleration
0.0Confidence
72.0Annual Revenue6
Quarterly Revenue12
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality7.7 / 25
Capital Efficiency0.0 / 20
Balance Sheet12.5 / 15
Shareholder Economics5.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Negative FCF · HIGHLatest free cash flow is negative.
Operating margin compression · MEDIUMOperating margin compressed by 1278.2446 percentage points.
Heavy share dilution · HIGHDiluted share count increased 83.6367%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
ROIC declining · MEDIUMROIC declined by 157.2051 percentage points.
Key Metrics
Revenue Growth TTM-76.67%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin-1,544.38%OK
FCF Margin-1,224%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-230.35%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO1.02xOK
Diluted Share Growth 1Y83.64%OK
SBC / Revenue117.45%OK
SBC / FCF-9.6%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $0.00 | $0.00 | -$48.95M | -$44.78M | -$45.71M | n/a | n/a | n/a | -162.88% | 61.34M |
| 2025 FY Dec 31, 2024 | $1.32M | $1.32M | -$42.91M | -$34.29M | -$34.63M | 100% | -3,244.87% | -2,618.65% | -1,140.96% | 9.26M |
| 2024 FY Dec 31, 2023 | $2.24M | $2.24M | -$38.08M | -$25.12M | -$25.32M | 100% | -1,700.56% | -1,130.71% | -359.27% | 5.52M |
| 2023 FY Dec 31, 2022 | $23.90M | $23.90M | -$28.92M | -$23.46M | -$25.63M | 100% | -120.97% | -107.2% | -213.96% | 4.35M |
| 2021 FY Dec 31, 2021 | $60.88M | $60.88M | -$13.39M | $1.99M | -$8.96M | 100% | -22% | -14.71% | -66.67% | 27.34M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.48M | sum latest 4 fiscal quarters Revenue | OK | 0000950170-24-122443, 0000950170-25-067554 |
| Revenue Growth TTM | -76.67% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000950170-24-122443, 0000950170-25-067554 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001833214-26-000003 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001833214-26-000003 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001833214-26-000003 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000950170-24-122443, 0000950170-25-067554 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0000950170-24-122443, 0000950170-24-094084 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0000950170-24-122443, 0000950170-25-067554 |
| Operating Margin | -1,544.38% | Operating Income / Revenue | OK | 0000950170-24-122443, 0000950170-25-067554 |
| FCF Margin | -1,224% | (CFO - CapEx) / Revenue | OK | 0000950170-24-122443, 0000950170-24-094084 |
| ROIC | -230.35% | NOPAT / Average Invested Capital | OK | 0000950170-24-122443, 0000950170-25-067554 |
| Net Debt / CFO | 1.02x | Net Debt / CFO | OK | 0000950170-24-122443, 0000950170-24-094084 |
| Current Ratio | 3.69x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 117.45% | SBC / Revenue | OK | 0000950170-24-122443, 0000950170-24-094084 |